OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Lee on Early Efficacy Data With Cirmtuzumab/Ibrutinib in MCL

June 10th 2020

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 10th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPC

June 10th 2020

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

Dr. Musher on Immunotherapy Versus TKIs in HCC

June 10th 2020

Benjamin Leon Musher, MD, discusses immunotherapy versus TKIs in hepatocellular carcinoma.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 10th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Cortes on Updated PFS Data From KEYNOTE-355 in PD-L1-High TNBC

June 9th 2020

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Flinn on the Role of BTK Inhibitors in CLL

June 9th 2020

Ian W. Flinn, MD, PhD, discusses the role of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Pemmaraju on the Challenges of Targeting TP53 Mutations in MDS/AML

June 9th 2020

Naveen Pemmaraju, MD, discusses the challenges of targeting TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.

Dr. Moreira on Launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer

June 9th 2020

Daniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.

Dr. Zakashansky on Repeat Exposure to PARP Inhibitors in Patients With Ovarian Cancer

June 9th 2020

Konstantin Zakashansky, MD, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 9th 2020

Hun Ju Lee, MD, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLC

June 9th 2020

Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping

Dr. Ruan on Stratifying Risk in MCL

June 9th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Neelapu on ALLO-501 Plus ALLO-647 in Relapsed/Refractory B-Cell Lymphomas

June 8th 2020

Sattva Neelapu, MD, discusses the mechanism of action of ALLO-501 when paired with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Dr. Ruan on Stratifying Risk in MCL

June 8th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).